Published in Clinical Trials Week, September 25th, 2006
Investigators working in Canada noted, "Atrial fibrillation (AF) is frequent in patients with chronic heart failure (CHF). Experimental and small patient studies have demonstrated that blocking the renin-angiotensin-aldosterone system may prevent AF."
"In the CHARM program," explained A. Ducharme and colleagues at the Montreal Heart Institute, "the effects of the angiotensin receptor blocker candesartan on cardiovascular mortality and morbidity were evaluated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.